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Introduction
The Wnt/β-catenin signaling pathway is a key regulator in numerous cellular processes including stem cell maintenance, fate decision and cell cycle control (1, 2) . Τhe main denominator of canonical Wnt signaling, β-catenin, has several cellular functions. At the cell membrane, it is associated with E-cadherin and participates in the formation of the adherens junctions (3) . In the cytoplasm, β-catenin can form complexes with a multitude of proteins, including the β-catenin destruction complex consisting of APC, AXIN2, GSK3β and CK1α (4, 5) . Tankyrase 1 and 2 (TNKS1/2) regulate the stability of the β-catenin destruction complex through AXIN2 by poly(ADP-ribosyl)ation (6) . While TNKS1/2 modulates the destruction complex, this complex interferes with TNKS. Evidence suggests that TNKS is phosphorylated in a cell cycle-dependent manner by GSK3β (7) . TNKS is furthermore controlled by the ubiquitin E3 ligase RNF146 that destabilizes TNKS1/2, AXIN2 and itself by ubiqitinylation (8, 9) . In the standard model, the destruction complex regulates the sequential phosphorylation of β-catenin by the kinases CK1α at S45 and by GSK3β at S33, S37 and T41. This leads to polyubiquitination by β-TrCP and subsequent degradation of β-catenin by the proteasome (10, 11) . Active Wnt signaling inhibits the function of the destruction complex, and β-catenin is not phosphorylated at the N-terminus and degraded but enters the nucleus. Nuclear uptake of β-catenin may be further enhanced by the context-dependent C-terminal phosphorylation of β-catenin at S675, leading to increased nuclear translocation (12) . In addition to canonical Wnt signaling, a variety of alternative cellular mechanisms may trigger altered nuclear accumulation of β-catenin. These mechanisms include the Hif-1a signaling pathway, down-regulation of E-cadherin or C-terminal phosphorylation of β-catenin through HGF-activated cMet (13) (14) (15) . Furthermore, PKA-involving mechanisms can lead to C-terminal phosphorylation of β-catenin and enhance its nuclear presence (12) . Recently it was discovered that the primary cilium diverts Jouberin from the nucleus and limits β-catenin nuclear entry (16) .
In the nucleus, β-catenin exerts a number of functions, such as binding to the transcription factor TCF/LEF by replacing Groucho and activation of downstream transcription of genes, including c-Myc, Cyclin D1 and AXIN2 (2) . Nuclear β-catenin levels are not only determined by the rate of β-catenin import to the nucleus, but also by "nuclear trapping" of β-catenin through factors such as TCF/LEF (17). Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 22, 2012 ; DOI: 10.1158/0008-5472. In general, mutations in genes encoding central components of the Wnt/β-catenin pathway and the destruction complex, lead to the accumulation of nuclear β-catenin and contribute to tumor initiation and progression (18, 19) . Wnt activating mutations are found in a broad range of solid tumors including colon cancer, gastric cancer, hepatocellular carcinoma, breast cancer, medulloblastoma, melanoma, non-small cell lung cancer, pancreas adenocarcinoma and prostate cancer (20) . It has been well established that the majority of intestinal neoplasia with deregulated Wnt signaling harbor truncating mutations in both alleles of the adenomatous polyposis coli (APC) tumor suppressor gene (21) .
Considerable efforts have been made to identify drugs that inhibit Wnt/β-catenin signaling (18, (22) (23) (24) (25) . Published inhibitory drugs that interact with biotargets directly associated with canonical Wnt signaling include WAY-316606 for SFRP (26) , Niclosamide for frizzled (27) , NCS668036 for Dsh (28) , Pyrvinium for CK1 (24) , XAV939 and IWR-1 for TNKS1/2 (4,22), 2,4-diamino-quinazoline, Quercetin, PKF115-584 and ICG-001 for β-catenin and its binding to TCF or CREB (29) (30) (31) (32) .
TNKS1/2, in particular, are promising biotargets for pharmaceutical reagents (4, 6) . TNKS1/2 is not only involved in controlling canonical Wnt signaling, but has been associated with further cellular processes through either protein poly(ADP-ribosyl)ation (PARsylation), or by protein complex formation. These are: (i) Telomere maintenance by interacting with TRF1 (33); (ii) spindle formation and stabilization by binding to NuMA (33) ; and (iii) glucose metabolism by regulating GLUT4 transport through IRAP (33) .
In the present work we have identified a novel TNKS inhibitor, JW55, which inhibits the PARP domain of TNKS1/2, leading to the stabilization of AXIN2 followed by increased degradation of β-catenin. JW55 efficiently decreases canonical Wnt signaling in colon carcinoma cell lines, in a Xenopus axis duplication assay, and in tamoxifen-induced tumors in 
Materials and Methods

Cell lines and luciferase assays
All cell lines were purchased from ATCC (American Type Culture Collection) and maintained and treated according to the supplier's recommendations. Reporter assays were performed as previously described (34) . IncuCyte cell growth measurement assay 1,000 SW480 or RKO cells were seeded in 96-well plates. The day after, the cell culture medium was exchanged to solutions that contained 0.1% DMSO or 10 µmol/L JW55 for RKO cells, and 0.1% DMSO or 10, 5 or 1 µmol/L JW55 for SW480 cells. All samples consisted of a minimum of six replicates. The plate was incubated in an IncuCyte TM (Essen BioScience) inside a cell culture incubator. Images were captured every second hour to monitor proliferation.
Colony assay
400 SW480, RKO or HeLa cells were seeded in 6 cm plates and 1% FBS. The day after, the medium was exchanged to 0.05% DMSO or 5 µmol/L JW55 for RKO and HeLa cells, and 0.1% DMSO or 5, 1 or 0.1 µmol/L JW55 for SW480 cells (minimum three replicates). The cells were grown until colonies appeared in the control plates and medium was changed twice a week.
The plates were stained and fixed with 0.2% methylene blue in methanol and washed with PBS.
The colonies were counted manually with a colony counter (Scienceware). Representative pictures of colonies were captured with a Leica MZ Apo Stereomicroscope connected to a Leica DC200 camera and Adobe Photoshop. 
Tumor initiation and treatment in
Other Materials and Methods
Please see previous descriptions (34) and Supplementary Materials and Methods.
Results
JW55 is a potent and selective inhibitor of the canonical Wnt pathway
To identify chemical compounds that inhibit the canonical Wnt signaling pathway, a library consisting of 37,000 small molecules (ChemBioNet) was screened using HEK293 cells that were stably transfected with a SuperTOP-d1EGFP reporter (34) . The vector contains a synthetic TCF-responsive promoter (SuperTOP: 7 x TCF binding sites) that initiates the expression of destabilized d1EGFP upon activation of canonical Wnt signaling (34) . Canonical
Wnt signaling was activated using conditioned media (CM) from L Wnt3a-expressing cells. The screen resulted in 77 primary hits including the previously described compounds JW67 and JW74
(34) and JW55 ( Fig 1A, right panel) . To evaluate the efficacy and specificity of JW55, the compound was tested in three different luciferase reporter assays. Wnt3a-induced HEK293 cells The selectivity and specificity of JW55 was further tested in an in vivo Xenopus axis duplication assay, a highly stringent test for examining inhibitors of canonical Wnt signaling.
When injected into the ventral blastomeres of four-cell stage X. laevis embryos, XWnt8 mRNA induced Wnt signaling resulting in the formation of a second body axis. By using selective Wnt inhibitors, the axis duplication can be inhibited and a normal phenotype restored (34) . Coinjection of 10 pg XWnt8 and 2 pmol of JW55 resulted in a significant 51% reduction of the axis duplication incidence in developing frog embryos when compared to the DMSO vehicle control (z-test, P = 0.001) (Fig. 1D, left) . This result provides evidence that JW55 acts as a specific and effective inhibitor of canonical Wnt signaling. 
JW55 regulates β-catenin stability at the level of the destruction complex
To identify the interference point of JW55 with canonical Wnt signaling, the effect of JW55 was monitored after LiCl-induced activation of the pathway. The activity of GSK3β, which is part of the β-catenin destruction complex, is reduced in the presence of LiCl (35) Next, the effect of JW55 on regulating the activity of β-catenin was tested. We used: (i) wild-type β-catenin and (ii) β-catenin with point mutations in the N-terminal phosphorylation sites (S33, S37, T41, S45) that resists degradation and functions as dominant active (da-Cat).
Plasmids containing full-length β-catenin or da-Cat, along with ST-Luc and Renilla, were transiently transfected in HEK293 cells. The expression of wild-type β-catenin led to an increased ST-Luc reporter activity that could be reduced by 55% when the transfected cells were exposed to 10 µmol/L of JW55 (normality test failed, rank sum test: P = 0.001) ( Fig. 2A, right) .
In contrast, the activation of the pathway by da-Cat could not be inhibited by 10 µmol/L JW55, further indicating that JW55 acts at the level or downstream of the destruction complex (normality test failed, rank sum test: P = 0.457) ( Fig. 2A, right) .
JW55 inhibits canonical Wnt signaling in colorectal cancer cell lines in vitro
Mutations in the APC gene, which occur in nearly all colorectal cancers (CRC) (18) 
JW55 destabilizes β-catenin by increasing cytoplasmic AXIN2 levels
Previous studies have shown that an increase in AXIN2 steady-state levels induced by TNKS1/2 or CK1a inhibitors is accompanied by a decrease in β-catenin concentrations (4, 22, 24, 34) . Increased levels of AXIN2 protein promote degradation of β-catenin even in cells with truncated APC (4, 22, 38) . Western Blot analysis of SW480 cells lysates revealed a dosedependent increase of cytoplasmic AXIN2 after JW55 treatment (range: 10 µmol/L -100 nM) ( Fig. 3A and Supplementary Fig. S2 ). Furthermore, an antibody against the active and nonphosphorylated form of β-catenin (active β-catenin, ABC) identified reduced levels of β-catenin in the cytoplasm of JW55-treated cells (Fig. 3A and Supplementary Fig. S2 ). In addition, a modest reduction of total β-catenin and a substantial decrease of nuclear ABC were observed, and an increase in phosphorylated β-catenin (pβ-catenin) levels was seen indicating ongoing β-catenin degradation (Fig. 3A and Supplementary Fig. S2 ).
To gain further insight into the changes in cellular distribution of AXIN2 and β-catenin, JW55-treated SW480 cells were analyzed by immunofluorescence. A general reduction of total β-catenin, both in the cytoplasmic and nuclear compartments, was detected at the doses of 5 and 1 µmol/L (equal shutter speed) ( Supplementary Fig. S3 ). Confocal microscopy (equal shutter 
speeds) revealed, in accordance with the Western blot analysis, that the levels of cytoplasmic AXIN2 were significantly increased (Fig. 3B ) and large protein foci, probably representing accumulated destruction complexes, were observed (Fig. 3B, arrows) . Clusters of co-localized cytoplasmic β-catenin and AXIN2 have previously been detected in SW480 cells after treatment with the Wnt antagonist JW74 (34) . Similar to JW74, enhanced phosphorylation and resulting degradation of β-catenin after JW55 exposure appeared to be orchestrated by stabilization of AXIN2 in the destruction complex (Fig. 3 and 5) .
JW55 specifically inhibits the PARsylation activity of TNKS1 and TNKS2
By inhibiting the PARP domain of TNKS1/2, XAV939, IWR-1 and JW74 prevent autoPARsylation of TNKS1/2 and PARsylation of AXIN2 (4, 22, 39, 40) . This leads to a stabilization of AXIN2, an accumulation of proteins in the destruction complex followed ultimately by an increased degradation of β-catenin (4, 22) . To test whether JW55 decreased canonical Wnt signaling by directly inhibiting the PARP domain of TNKS1/2 we performed biochemical assays for monitoring the activity of TNKS1/2 and PARP. JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC 50 -values of 1.9 μmol/L and 830 nmol/L, respectively ( Fig. 4A and Supplementary Fig. S1C ). However, in contrast to XAV939 (4) (Fig. 4A and Supplementary Fig.   S1D ) but similar to IWR-1 (4), JW55 exhibited no inhibition of PARP1 at doses up to 20 μmol/L (Fig. 4A) . Although further details may emerge, present evidence suggests that JW55 decreases canonical Wnt signaling by specifically inhibiting the PARP domain of TNKS1/2 ( Fig. S4 ). Binding of JW55 to recombinant TNKS2 protein was also observed using a fluorescence polarization competition assay, with a structurally similar but inactive analog as a negative control (41) (Supplementary Fig. S5 ). Interestingly, opposite to the effect of XAV939 and IWR-1 (4), a decrease in endogenous TNKS1/2 levels was detected after exposure to JW55 (Fig. 4D) . 
canonical Wnt signaling would affect CRC cell growth. First, SW480 cells were incubated with 10 µmol/L JW55 and labeled with BrdU and propidium iodide. The subsequent flow cytometry cell cycle analysis revealed that JW55 treatment lowered the proportion of cells in the S phase (from 28.4% in DMSO-treated controls to 22.2%), raised moderately the cell fraction in the G1 phase (from 37.3% to 38.8%) and increased the number of cells in G2/M phase (from 34.3% to 39%) (Fig. 6A) .
Next, we monitored the cell proliferation kinetics using IncuCyte. SW480 cells were exposed to 10, 5 or 1 µmol/L of JW55 for nine days and the confluency was measured every two hours. All doses of JW55 reduced SW480 cell growth and the most robust effect was detected at a dose of 10 µmol/L JW55. The confluency was reduced to 55% relative to the DMSO control at the end of experiment (Fig. 6B) . In parallel, the colorectal cancer cell line RKO, which contains wild-type APC and β-catenin and exerts Wnt-independent cell growth, was used as a control.
RKO cells reached 100% confluency within seven days and were not affected by treatment with 10 µmol/L JW55 (Fig. 6B) . (Fig. 6D, left) . All SW480 colonies, which formed in the presence of JW55, were substantially smaller (Fig. 6D, right) .
Taken together, these data show that JW55-mediated inhibition of canonical Wnt signaling resulted in reduced cell cycle progression, proliferation and colony formation in the CRC cell line SW480 in vitro.
JW55 reduces tumor development in conditional Apc knock-out mice
Recently, the leucine-rich-repeat containing G-protein-coupled receptor 5 (Lgr5) was 26.0) (normality test failed, rank sum test: P = 0.057) (Fig. 7C, lower panel) . Furthermore, a significant decrease of the total tumor area was noticed after injections with JW55 (mean: 0.022 mm 2 ) when compared to the control group (mean: 0.154 mm 2 ) (Students t-test: P = 0.009) (Fig.   7C , lower panel). The area of single tumors was significantly reduced after injections with JW55
(mean: 0.0025 mm 2 ) when compared to the untreated group (mean: 0.0049 mm 2 ) (Students t-test: P = 0.043) (Fig. 7C, lower panel) . Interestingly, the proportion of cells that expressed Ki67, a marker of proliferating and ISC-like cells (50), was substantially decreased in adenomas exposed to JW55 when compared to tumors that developed in the control mice (Fig. 7B, panel h and i) . Importantly, when examining the healthy mucosa with antibodies against various epithelial cell populations, such as EphB2 for ISCs and Krt20 for terminally differentiated epithelial cells (50), we did not observe changes in its morphology, proliferation or differentiation after exposure to JW55 (Fig. 7D) . In summary, the results obtained from JW55-treated conditional Apc knock-out mice indicate that in vivo small-molecular inhibition of TNKS1/2 leads to decreased canonical Wnt signaling followed by reduced adenoma induction and possibly progression of adenomacarcinoma.
Discussion
Altered properties of Wnt/β-catenin signaling are enabling factors for a multitude of diseases, including cancer. Amongst known interference points in the canonical Wnt signaling pathway, the PARP domains of TNKS1/2 seem to be a particular suitable target for inhibiting the pathway. Blocking the PARP domain of TNKS1/2 with low molecular inhibitors, such as XAV939, IWR-1 and JW74 (4, 34) , leads to the stabilization of the destruction complex that triggers increased degradation of β-catenin (19) . As predicted for a TNKS inhibitor, we observed a massive cytoplasmic accumulation of AXIN2 after treatment with 500 nmol/L JW55, followed by a significant reduction of β-catenin levels in vitro (Fig. 5) . A similar stabilization of AXIN2 was also seen with JW74, XAV939 and IWR-1 (4, 22, 34) . However, despite the substantial increased specificity of JW55 to the PARP domain of TNKS1/2 when compared to XAV939, we cannot rule out that JW55 may affect additional mechanisms that contribute to the observed effects in colon cancer cell lines and in Apc CAN-11-3336 and the small intestine. Interestingly, in our setting, the exposure of progenitor cells in a normal crypt to JW55 did not exert visible alterations in the intact mucosa as measured with the markers EphB2, Ki67 and Krt20. However, we cannot exclude that a longer treatment may cause reduction in cell turnover in the intestine epithelium (45) . The efficient in vivo reduction of adenomas in mice and CRC growth in vitro by a tankyrase specific inhibitor further strengthens the importance of TNKS and β-catenin as potential therapeutic biotargets. TNKS1/2 are members of a family of five PARP proteins in humans, including PARP1, which is an extensively explored target for drug development (33) 
